Currently submitted to: JMIR Preprints
Date Submitted: Mar 7, 2024
Open Peer Review Period: Mar 7, 2024 - Feb 20, 2025
(currently open for review and needs more reviewers - can you help?)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
The effect of casirivimab and imdevimab combination versus standard antiviral therapy on coronavirus swab result at discharge in hospitalized COVID-19 patients
ABSTRACT
Background:
The Corona Virus Disease of 2019 (COVID-19) pandemic motivates research efforts to address this catastrophe from the beginning of 2020 year up to the present. The year 2021 is coming to an end, and there have been several developments in pharmacotherapy for COVID-19. In terms of antiviral therapy, monoclonal antibody combinations become one of COVID-19 immunotherapy. Remdesivir and Favipiravir are the two antiviral medications typically used to treat COVID-19.
Objective:
The purpose of this study compares the effects of a combination of antibodies (casirivimab and imdevimab), remdesivir, and favipiravir on COVID-19 swab results in COVID-19 hospitalized patients at discharge.
Methods:
In this study, 265 COVID-19 patients with polymerase chain reaction (PCR) confirmation and indications for antiviral medication were non-randomized into three groups with a ratio of (1:2:2): REGN3048-3051(group A); Remdesivir (group B); Favipiravir (group C). Non-Randomized Single-blind Controlled study was the study design. The study's medication is provided by Hospital of Mansoura University. Following ethical permission, the study was conducted for approximately 6 months.
Results:
Compared to Remdesivir and Favipiravir, casirivimab and imdevimab cause more negative swab results at discharge. The three antivirals also have no significant adverse effects. All three antivirals are considered safe with these findings. Casirivimab and imdevimab achieve more negative swab results than Remdesivir & Favipiravir.
Conclusions:
Casirivimab & imdevimab achieve more negative swab results than Remdesivir and Favipiravir. All three antivirals are safe with no significant toxicity. Clinical Trial: Clinical Trial Registration: Clinicaltrials.gov, NCT05502081
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.